Advanced Therapy Medicinal Products Market to Exceed USD 245.1 Billion by 2034, Expanding at 16.6% CAGR Amid Rising Cell and Gene Therapy Demand

The global advanced therapy medicinal products (ATMPs) market was valued at US$ 45.8 Bn in 2023 and is projected to advance at a CAGR of 16.6% from 2024 to 2034, reaching more than US$ 245.1 Bn by the end of 2034. Increasing demand for tissue engineering, cell therapy, and gene therapy across oncology, musculoskeletal disorders, orthopedics, neurology, cardiology, and other indications is driving market development.

ATMPs encompass cell therapy, gene therapy, tissue-engineered medicines, and somatic-cell therapy medicines. These therapies are designed to address the underlying causes of diseases and disorders by augmenting, repairing, replacing, or regenerating organs, tissues, cells, genes, and metabolic processes.

The expansion of the cell therapy pipeline, increasing investment in clinical trials, rising prevalence of neurodegenerative diseases, growing demand for advanced gene therapies, an aging population, and the burden of genetic disorders are contributing to the rapid growth of the market.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31298

Advanced Therapies Transform the Disease Treatment Landscape

The emergence of ATMPs has transformed the pharmaceutical industry by creating new approaches for treating diseases that have historically been difficult or impossible to treat. Advanced therapies are also opening new treatment avenues for several types of cancer and other serious disorders.

The success of products such as Kymriah and Zolgensma has contributed to growing interest in the ATMP landscape. Pharmaceutical companies and biotechnology companies are increasingly investing in the development and commercialization of advanced therapies, while research institutions are exploring new approaches to tissue engineering and regenerative medicine.

Expansion of facilities supporting tissue engineering is also expected to contribute to market development. In October 2023, a research announcement sought to leverage the unique environment of the International Space Station (ISS) to advance tissue engineering and biomanufacturing.

The ISS National Laboratory solicited concepts for applied research and technology development focused on regenerative medicine applications, including space-based manufacturing and production activities intended to demonstrate technologies for terrestrial applications. Multiple projects were expected to receive funding supporting project costs, hardware and integration costs, and flight allocation to the orbiting laboratory.

Rising Number of Clinical Trials Drives Market Expansion

Increasing numbers of clinical trials for advanced therapies are strengthening the ATMP market pipeline. According to an article published in Nature Reviews Drug Discovery in June 2021, 2,073 cell therapies in the global pipeline were marked as active as of April 16, 2021, representing an increase of 572 compared with the 2020 update.

A growing number of cell and gene therapies are progressing through clinical and regulatory pathways. In March 2024, atidarsagene autotemcel, a gene-edited cell therapy developed by Orchard Therapeutics, was approved by the U.S. FDA for children with specified forms of metachromatic leukodystrophy. The therapy had previously received approval in the European Union, the U.K., Iceland, Switzerland, Liechtenstein, and Norway under the name Libmeldly.

In February 2024, jCyte, Inc. announced the successful outcome of its pre-phase 3 Type B meeting with the U.S. Food and Drug Administration held on January 16, 2024. The company was preparing to commence its pivotal U.S. trial in the second half of 2024 for its work in preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders.

On February 1, 2024, the U.S. FDA granted fast track designation to BST02, a T-cell therapy being developed for patients with liver cancer, including hepatocellular carcinoma and cholangiocarcinoma. BST02 is an adoptive immune cell therapy based on the expansion of tumor-infiltrating lymphocytes derived from a patient's cells.

The growing number of therapies progressing through clinical trials and regulatory pathways is expected to strengthen the ATMP market pipeline and support revenue growth.

Increasing Competition Encourages Investment in ATMP Development

Competition among pharmaceutical and biotechnology companies is becoming an important market driver. Recent ATMP approvals have encouraged conventional pharmaceutical companies to explore advanced therapies as potential future healthcare revenue streams.

The success of approved ATMP products has encouraged companies to increase investment in clinical development. Market participants are also adopting different operating models to accelerate manufacturing and commercialization. While some companies are establishing in-house production capabilities, others are relying on third-party service providers, including contract manufacturing organizations.

Acquisitions have also become an important strategy for companies seeking to enter or expand their presence in advanced therapies. Following approvals of products including Luxturna, Yescarta, and Kymriah, several organizations pursued acquisitions of companies developing CAR T-cell therapies.

Notable examples include Gilead Life Sciences' acquisition of Kite Pharma, Novartis' acquisition of AveXis, and Celgene's acquisition of Juno Therapeutics. Such transactions have helped established pharmaceutical companies strengthen their presence in advanced therapy markets.

The competitive environment is also encouraging investment in next-generation therapies. In October 2021, Leucid Bio announced an investment of US$ 15.26 Mn for the development of next-generation CAR-T therapies.

In June 2021, Blackstone Life Sciences collaborated with Cellex Cell Professionals and Intellia Therapeutics to launch a new CAR-T cell therapy company. Such collaborations and investments are contributing to the development of the ATMP ecosystem.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31298

North America Leads the Advanced Therapy Medicinal Products Market

North America dominates the global advanced therapy medicinal products market. High healthcare expenditure, established clinics and hospitals, and access to modern diagnostic and treatment technologies are among the factors supporting the region's leadership.

The North American market is characterized by strong activity in gene therapy and tissue engineering. The tissue engineering segment holds a slightly higher market share in the region, supported by growth in the geriatric population and increasing incidence of chronic diseases.

Availability of advanced technologies for the diagnosis and treatment of chronic disorders is further strengthening regional market development. Private and government funding and high healthcare expenditure also contribute to North America's significant share.

The combination of healthcare infrastructure, funding availability, advanced treatment capabilities, and growing demand for innovative therapies is expected to maintain North America's leading position during the forecast period.

Competitive Landscape

The advanced therapy medicinal products market is fragmented, with a large number of companies operating across cell therapy, gene therapy, and tissue engineering. Market participants are increasingly engaging in partnerships and collaborations to strengthen their positions and expand their product pipelines.

Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., MEDIPOST, Vericel Corporation, PHARMICELL Co., Ltd., and Organogenesis Inc. are among the prominent companies operating in the market.

Companies are pursuing different strategies, including clinical development, partnerships, collaborations, acquisitions, and investments in manufacturing capabilities. The competitive landscape is being shaped by the increasing number of advanced therapies entering clinical and regulatory pipelines.

Each of the key players is profiled based on company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Future Outlook for the Advanced Therapy Medicinal Products Market

The ATMP market is positioned for rapid expansion as research activity, clinical trials, regulatory approvals, and commercial investment continue to increase. The growing focus on cell therapy, gene therapy, and tissue engineering is creating new opportunities for the treatment of serious and previously difficult-to-treat diseases.

Investment in clinical pipelines remains a major growth factor. The increasing number of therapies moving through development and approval pathways is strengthening the potential commercial pipeline, while competition among pharmaceutical and biotechnology companies is encouraging further research and development investment.

Tissue engineering and regenerative medicine also represent important areas of opportunity. Research into advanced biomanufacturing, including the exploration of space-based manufacturing environments, highlights the breadth of technological development occurring within the sector.

Partnerships, acquisitions, and collaborations are expected to remain important strategies as companies seek to access new technologies, expand therapy pipelines, and accelerate commercialization.

Advanced Therapy Medicinal Products Market Segmentation

The advanced therapy medicinal products market is segmented based on therapy type, indication, end-user, and region. By therapy type, the market includes cell therapy, gene therapy, and tissue engineering.

Based on indication, the market covers oncology, neurology, cardiology, dermatology, infectious diseases, musculoskeletal disorders, orthopedics, and other indications, including genetic disorders.

By end-user, the market is segmented into hospitals, specialty clinics, and other end-users, including research institutes.

Geographically, the market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, GCC countries, and South Africa.

Advanced Therapy Medicinal Products Market Snapshot

The global advanced therapy medicinal products market was valued at US$ 45.8 Bn in 2023 and is projected to reach more than US$ 245.1 Bn by 2034, advancing at a CAGR of 16.6% from 2024 to 2034. Historical data is available for 2020–2022, with quantitative analysis measured in US$ Bn.

The market assessment includes segment and regional analysis, along with qualitative evaluation of drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. The competition landscape includes company profiles covering business overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials.

Overall, increasing clinical-trial activity, growing investment in cell and gene therapies, rising competition among pharmaceutical and biotechnology companies, and continued development of tissue engineering and regenerative medicine are expected to remain major factors driving the advanced therapy medicinal products market through 2034.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=31298<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Multiomics Market

Epidermal Growth Factors (EGFs) Market

Next Generation Sequencers (NGS) Market

Genomic Surveillance/Sequencing Market

Exosome Isolation Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com